ArticleScientific reports2026
CiCLoDS: Joint cell clustering and gene selection for single-cell spatial transcriptomics.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CAGNet: a structure-aware clustering-alternated graph network for cell-cell interaction inference in spatial transcriptomics.BMC bioinformatics · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
Imaging-based spatial transcriptomic (ST) assays now profile targeted gene panels for hundreds of thousands of cells while preserving tissue context, yet most downstream analyses still need a compact, interpretable subset. We introduce CiCLoDS (Clustering in Critical & Low-Dimensional Subspace), an unsupervised framework adapted for spatial transcriptomics to jointly optimize clustering and feature selection under a strict, user-defined gene budget. The method returns an explicit feature subset aligned with the discovered partitions, accepts spatial side information via sine–cosine positional encodings, and converges in minutes on commodity CPUs. We benchmark CiCLoDS on three diverse datasets: Vizgen MERFISH mouse liver (1.27 M cells), 10x Xenium human colon (23 K cells), and Human DLPFC. On hepatocyte zonation, CiCLoDS raises the adjusted Rand index by up to +0.36 over PCA and geneBasis, preserves neighborhood structure with a kNN-overlap AUC of 0.89, and detects vessel-associated voids at 92.8% F1. On Human DLPFC (Visium), CiCLoDS demonstrates robust generalization, achieving a mean Adjusted Rand Index (ARI) of 0.40—surpassing BayesCafe (0.32)—and maintaining high accuracy on heterogeneous samples where baselines fail. Furthermore, we reveal a synergistic utility: using CiCLoDS to initialize BayesSpace raises the mean ARI to 0.50, resolving local minima issues to outperform either method alone. These results show that a lightweight, jointly optimized objective can achieve competitive accuracy, robust generalization, and synergistic utility while producing assay-ready feature panels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.